30 Aug 2013, BioSpectrum Bureau , BioSpectrum
Singapore: US-based ImmunoGen licensed a targeted anticancer antibody technology to Eli Lilly in a deal that could be worth $200 million in milestone payments plus royalties on sales of any commercialized drugs.The cancer-fighting technology uses antibodies to deliver potent cell-killing agents to cancer cells, sparing nearby healthy cells.
ImmunoGen presently has one product on the market using its technology, a cancer compound called Kadcyla. This is being sold in the US by Genentech, a firm that is owned by Roche Group.
Ten other compounds using ImmunoGen technology are being tested on patients, of which ImmunoGen wholly owns three.